Evidence map›Paper›PMID 23027623›Full record

ArticleCarcinogenesis2012

MAP kinase genes and colon and rectal cancer.

Martha L Slattery, Abbie Lundgreen, Roger K Wolff

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. The Mechanism ofCombinatorial chemistry & high throughput screening · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Martha L SlatteryDepartment of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT 84108, USA. marty.slattery@hsc.utah.edu
Abbie Lundgreen
Roger K Wolff
University of Utah · USUtah Department of Health · US

Funding

DIET, ACTIVITY &REPRODUCTION--RISKS FOR RECTAL CANCERR01CA048998 · NCI · UNIVERSITY OF UTAH · PI SLATTERY, MARTHA L · 1991 to 2012
$7.9M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067000 · PC · UNIVERSITY OF UTAH · PI WIGGINS, CHARLES L · 1996 to 2000
$1.3M
DIET, ACTIVITY &REPRODUCTION--RISKS FOR RECTAL CANCERU01CA048998 · NCI · UNIVERSITY OF UTAH · PI SLATTERY, MARTHA OR MARTY L · 1997 to 1999
–
NCI NIH HHS CA48998NCI NIH HHS N01-PC-67000NCI NIH HHS R01 CA048998NCI NIH HHS U01 CA048998
6 · The paper itself

Abstract

Mitogen-activated protein kinase (MAPK) pathways regulate many cellular functions including cell proliferation, differentiation, migration and apoptosis. We evaluate genetic variation in the c-Jun-N-terminal kinases, p38, and extracellular regulated kinases 1/2 MAPK-signaling pathways and colon and rectal cancer risk using data from population-based case-control studies (colon: n = 1555 cases, 1956 controls; rectal: n = 754 cases, 959 controls). We assess 19 genes (DUSP1, DUSP2, DUSP4, DUSP6, DUSP7, MAP2K1, MAP3K1, MAP3K2, MAP3K3, MAP3K7, MAP3K9, MAP3K10, MAP3K11, MAPK1, MAPK3, MAPK8, MAPK12, MAPK14 and RAF1). MAP2K1 rs8039880 [odds ratio (OR) = 0.57, 95% confidence interval (CI) = 0.38, 0.83; GG versus AA genotype] and MAP3K9 rs11625206 (OR = 1.41, 95% CI = 1.14, 1.76; recessive model) were associated with colon cancer (P (adj) value < 0.05). DUSP1 rs322351 (OR = 1.43, 95% CI = 1.09, 1.88; TT versus CC) and MAPK8 rs10857561 (OR = 1.48, 95% CI 1.08, 2.03; AA versus GG/GA) were associated with rectal cancer (P (adj) < 0.05). Aspirin/non-steroidal anti-inflammatory drug, cigarette smoking and body mass index interacted with several genes to alter cancer risk. Genetic variants had unique associations with KRAS, TP53 and CIMP+ tumors. DUSP2 rs1724120 [hazard rate ratio (HRR) = 0.72, 95%CI = 0.54, 0.96; AA versus GG/GA), MAP3K10 rs112956 (HRR = 1.40, 95% CI = 1.10, 1.76; CT/TT versus CC) and MAP3K11 (HRR = 1.76, 95% CI 1.18, 2.62 TT versus GG/GT) influenced survival after diagnosis with colon cancer; MAP2K1 rs8039880 (HRR = 2.53, 95% CI 1.34, 4.79 GG versus AG/GG) and Raf1 rs11923427 (HRR = 0.59 95% CI = 0.40, 0.86; AA versus TT/TA) were associated with rectal cancer survival. These data suggest that genetic variation in the MAPK-signaling pathway influences colorectal cancer risk and survival after diagnosis. Associations may be modified by lifestyle factors that influence inflammation and oxidative stress.

Indexed as

AdultAgedAnti-Inflammatory Agents, Non-SteroidalCase-Control StudiesColonic NeoplasmsFemaleGenetic VariationGenotypeHumansMaleMAP Kinase Signaling SystemMiddle AgedMitogen-Activated Protein KinasesPolymorphism, Single NucleotideRectal NeoplasmsSmokingAnti-Inflammatory Agents, Non-SteroidalMitogen-Activated Protein Kinases

Identifiers

PMID23027623
PMCPMC3510742
OpenAlexW2132946679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.